Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.…
Molecular Partners to Present at Inaugural UBS Global Biopharma Conference
Molecular Partners (NASDAQ: MOLN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 134 employees.
The shares were at 2.525 USD on 20 November 2026, down 33.0% over 52 weeks. Its 52-week range is 2.525 USD to 5.360 USD, and it trades at the bottom of that range.
Its market capitalisation is 96.80M USD.
Molecular Partners reports return on equity of -76.7% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 54.75M CHF. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 5 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 10.01 USD is 296.4% above the current price. The next earnings report is expected on 5 March 2027.